These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989 [TBL] [Abstract][Full Text] [Related]
3. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476 [TBL] [Abstract][Full Text] [Related]
4. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081 [TBL] [Abstract][Full Text] [Related]
5. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510 [TBL] [Abstract][Full Text] [Related]
6. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917 [TBL] [Abstract][Full Text] [Related]
7. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042 [TBL] [Abstract][Full Text] [Related]
8. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases? Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240 [TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results. Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949 [TBL] [Abstract][Full Text] [Related]
11. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI]. Pfannenberg C; Schwenzer N Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421 [TBL] [Abstract][Full Text] [Related]
12. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study. Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959 [TBL] [Abstract][Full Text] [Related]
13. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study. Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer staging in a single session: whole-body PET/CT mammography. Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831 [TBL] [Abstract][Full Text] [Related]
15. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Aquino SL; Fischman AJ Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753 [TBL] [Abstract][Full Text] [Related]
16. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. Queiroz MA; Kubik-Huch RA; Hauser N; Freiwald-Chilla B; von Schulthess G; Froehlich JM; Veit-Haibach P Eur Radiol; 2015 Aug; 25(8):2222-30. PubMed ID: 26017734 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124 [TBL] [Abstract][Full Text] [Related]
18. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984 [TBL] [Abstract][Full Text] [Related]
19. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. Albano D; Patti C; Lagalla R; Midiri M; Galia M J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267 [TBL] [Abstract][Full Text] [Related]